Modality
Fusion Protein
MOA
WEE1i
Target
CD38
Pathway
Autophagy
SCLC
Development Pipeline
Preclinical
~Feb 2022
→ ~May 2023
Phase 1
Aug 2023
→ Jul 2028
Phase 1Current
NCT04987689
1,150 pts·SCLC
2024-05→2027-12·Completed
NCT06012013
1,382 pts·SCLC
2023-08→2028-07·Recruiting
2,532 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-12-221.7y awayInterim· SCLC
2028-07-222.3y awayInterim· SCLC
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1
Recruit…
P1
Complet…
Catalysts
Interim
2027-12-22 · 1.7y away
SCLC
Interim
2028-07-22 · 2.3y away
SCLC
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04987689 | Phase 1 | SCLC | Completed | 1150 | SRI-4 |
| NCT06012013 | Phase 1 | SCLC | Recruiting | 1382 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 |